BioXcel Fuels Operations with $3.1M Equity Raise Amidst Zero Revenue

TL;DR

**BTAI is burning cash and diluting shareholders to stay afloat; avoid until they show a path to revenue.**

AI Summary

BioXcel Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three months ended June 30, 2025, was not explicitly stated but can be inferred from the lack of revenue and ongoing operational expenses. A significant financial event was the March 2025 offering, which included the issuance of 1,000,000 shares of common stock and warrants to purchase 1,000,000 shares, generating gross proceeds of $3.1 million. This offering, along with a registered direct offering in November 2024, which raised $6.6 million, indicates a reliance on equity financing to fund operations. The company also issued warrants to Oaktree and QIA in November 2024 and December 2023. BioXcel continues to manage its equity incentive plans, with 3,102,000 shares available for future awards under the 2020 Incentive Award Plan and 662,000 shares under the 2020 Employee Stock Purchase Plan as of June 30, 2025. The company's strategic outlook remains focused on its pipeline, funded by these capital raises, but faces ongoing risks related to clinical development and market acceptance.

Why It Matters

For investors, BioXcel's continued reliance on equity financing, evidenced by the $3.1 million March 2025 offering and $6.6 million November 2024 offering, signals ongoing cash burn without a clear path to revenue generation. This dilutes existing shareholder value and raises questions about long-term sustainability in a competitive biotech landscape where peers are either generating revenue or have more robust funding. Employees face potential job insecurity if clinical trials falter or further funding becomes difficult to secure. Customers, primarily future patients, are impacted by the pace and success of drug development, which is directly tied to the company's financial health. The broader market will watch to see if BioXcel can translate its pipeline into commercial success, influencing investor sentiment for early-stage biotechs.

Risk Assessment

Risk Level: high — The company reported no revenue for the three and six months ended June 30, 2025, and relies heavily on equity financing, as evidenced by the $3.1 million gross proceeds from the March 2025 offering and $6.6 million from the November 2024 offering. This indicates a high burn rate and significant dilution risk for investors, with no immediate signs of profitability.

Analyst Insight

Investors should exercise extreme caution and consider avoiding BTAI given its lack of revenue and continuous reliance on dilutive equity offerings. Monitor for significant clinical trial milestones or a clear path to commercialization before considering an investment.

Financial Highlights

revenue

$0

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating no commercial products generating sales)
• $3.1M — Gross Proceeds (from the March 2025 offering, highlighting reliance on equity financing)
• $6.6M — Gross Proceeds (from the November 2024 registered offering, further demonstrating capital raising efforts)
• 1,000,000 — Shares Issued (in the March 2025 offering, contributing to shareholder dilution)
• 3,102,000 — Shares Available (for future awards under the 2020 Incentive Award Plan as of June 30, 2025, indicating potential future dilution)

Key Players & Entities

• BioXcel Therapeutics, Inc. (company) — filer of the 10-Q
• Oaktree (company) — recipient of warrants in November 2024
• QIA (company) — recipient of warrants in November 2024
• Jefferies (company) — underwriter for equity offerings
• $3.1 million (dollar_amount) — gross proceeds from March 2025 offering
• $6.6 million (dollar_amount) — gross proceeds from November 2024 registered offering
• 1,000,000 (dollar_amount) — shares of common stock issued in March 2025 offering
• 3,102,000 (dollar_amount) — shares available under 2020 Incentive Award Plan as of June 30, 2025
• 662,000 (dollar_amount) — shares available under 2020 Employee Stock Purchase Plan as of June 30, 2025

FAQ

Risk Factors

• Reliance on Equity Financing [high — financial]: The company has raised $3.1 million in March 2025 and $6.6 million in November 2024 through equity offerings. This reliance on external capital to fund operations, particularly clinical development, exposes the company to market volatility and potential dilution.
• Clinical Development Risks [high — operational]: BioXcel's strategic outlook is focused on its pipeline, which is subject to the inherent risks of clinical trials, including potential delays, failure to demonstrate efficacy or safety, and regulatory hurdles.
• Market Acceptance of Pipeline Drugs [medium — market]: Even if clinical trials are successful, the company faces the risk of market acceptance for its drug candidates, which depends on factors like physician adoption, patient demand, and competitive offerings.
• Ongoing Operational Expenses [high — financial]: Despite no revenue, the company incurs ongoing operational expenses related to research and development, general and administrative functions, and clinical trial management, necessitating continuous funding.
• Warrant Dilution [medium — financial]: The issuance of warrants in multiple offerings (March 2025, November 2024, December 2023) to investors like Oaktree and QIA, along with equity incentive plans, creates potential future dilution for existing shareholders.

Industry Context

BioXcel Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing novel therapies. The sector is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight from bodies like the FDA. Success hinges on innovation, clinical trial outcomes, and effective commercialization strategies in a landscape with both established players and emerging biotech firms.

Regulatory Implications

As a clinical-stage biopharmaceutical company, BioXcel is subject to rigorous regulatory scrutiny from agencies like the FDA. Approval pathways for its drug candidates are complex and depend on demonstrating safety and efficacy through extensive clinical trials. Any delays or adverse findings in these trials can significantly impact the company's development timeline and future prospects.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates closely, as these are the primary drivers of future value.
2. Assess the company's cash burn rate and runway, given the lack of revenue and reliance on equity financing.
3. Evaluate the potential dilution from outstanding warrants and equity incentive plans.
4. Consider the competitive landscape and the market potential for BioXcel's pipeline candidates.

Key Dates

• 2025-06-30: Quarter End — Reporting period for the 10-Q, showing no revenue and significant shares available under incentive plans.
• 2025-03-03: March 2025 Offering — Raised $3.1 million in gross proceeds through the issuance of common stock and warrants, highlighting continued reliance on equity financing.
• 2024-11-21: Registered Offering — Raised $6.6 million in gross proceeds, further demonstrating the company's strategy of using equity markets to fund operations.
• 2024-11-21: Warrant Issuance to Oaktree and QIA — Part of the November 2024 offering, contributing to potential future share dilution.
• 2023-12-05: Warrant Issuance to Oaktree and QIA — Indicates ongoing strategic financial arrangements and potential future dilution.
• 2024-03-25: Registered Direct Offering — Previous capital raise event, contributing to the company's funding strategy.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial and operational information for BioXcel Therapeutics for the specified quarter.)

Warrants

A type of derivative that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (BioXcel has issued warrants in multiple offerings, which represent potential future dilution of common stock.)

Incentive Award Plan

A plan established by a company to grant equity-based compensation, such as stock options or restricted stock units, to employees and executives. (BioXcel has a significant number of shares available under its 2020 Incentive Award Plan, indicating potential future equity compensation and dilution.)

Registered Direct Offering

A type of public offering where a company sells newly issued securities directly to a small group of institutional investors. (BioXcel has utilized this method to raise capital, as seen in the November 2024 and March 2025 offerings.)

Gross Proceeds

The total amount of money raised from an offering before deducting any underwriting fees or other expenses. (The $3.1 million and $6.6 million in gross proceeds highlight the scale of BioXcel's recent equity financing efforts.)

Year-Over-Year Comparison

For the three and six months ended June 30, 2025, BioXcel Therapeutics reported $0 in revenue, consistent with the prior year's periods. The company continues to rely on equity financing, with recent offerings in March 2025 ($3.1 million) and November 2024 ($6.6 million) to fund its operations and pipeline development. No significant changes in risk factors are apparent, with the ongoing reliance on capital raises and clinical development risks remaining prominent.

Key Financial Figures

• $0.001 — e on which registered Common Stock , $0.001 par value per share BTAI Nasdaq Cap

Filing Documents

• btai-20250630x10q.htm (10-Q) — 2792KB
• btai-20250630xex31d1.htm (EX-31.1) — 17KB
• btai-20250630xex31d2.htm (EX-31.2) — 17KB
• btai-20250630xex32d1.htm (EX-32.1) — 10KB
• btai-20250630xex32d2.htm (EX-32.2) — 8KB
• btai-20250630x10q006.jpg (GRAPHIC) — 91KB
• btai-20250630x10q007.jpg (GRAPHIC) — 79KB
• 0001558370-25-011158.txt ( ) — 11174KB
• btai-20250630.xsd (EX-101.SCH) — 63KB
• btai-20250630_cal.xml (EX-101.CAL) — 44KB
• btai-20250630_def.xml (EX-101.DEF) — 294KB
• btai-20250630_lab.xml (EX-101.LAB) — 561KB
• btai-20250630_pre.xml (EX-101.PRE) — 444KB
• btai-20250630x10q_htm.xml (XML) — 1950KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Forward Looking Statements

Forward Looking Statements 3 Summary Risk Factors 4 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 7 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 7 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 8 Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity for the three and six months ended June 30, 2025 and 2024 9 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 39 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 67 Item 4.

Controls and Procedures

Controls and Procedures 67

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 68 Item 1A.

Risk Factors

Risk Factors 68 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 133 Item 3. Defaults Upon Senior Securities 133 Item 4. Mine Safety Disclosures 133 Item 5. Other Information 133 Item 6. Exhibits 134

Signatures

Signatures 136 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The words "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements contained in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: our sales strategy for IGALMI ; strategy relating to, anticipated benefits from, and cost savings from our Reprioritization (as defined herein); our ability to raise additional capital and continue as a going concern; developments relating to our TRANQUILITY program; the size of our total addressable markets and related underlying estimates; our plans relating to clinical trials and marketing applications for our product candidates; our plans to research, develop and commercialize our current and future product candidates; our plans to seek to enter into collaborations for the development and commercialization of certain product candidates; the potential benefits of any future collaboration; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the timing of and results of discussions we have with regulators; the rate and degree of market acceptance, clinical utility, number of p

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements BIOXCEL THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands, except per share amounts) June 30, 2025 December 31, (unaudited) 2024 ASSETS Current assets Cash and cash equivalents $ 17,435 $ 29,854 Restricted cash 1,140 — Accounts receivable, net 17 131 Inventory 506 679 Prepaid expenses 5,150 5,290 Other current assets 995 1,440 Total current assets 25,243 37,394 Property and equipment, net 324 475 Operating lease right-of-use assets 222 382 Other assets — 87 Total assets $ 25,789 $ 38,338 LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY Current liabilities Accounts payable $ 16,692 $ 15,990 Accrued expenses 5,090 5,762 Current portion of long-term debt 11,216 — Due to related parties 122 107 Other current liabilities 256 374 Total current liabilities 33,376 22,233 Long-term portion of operating lease liabilities — 65 Derivative liabilities 2,611 6,633 Long-term debt 97,469 102,508 Total liabilities 133,456 131,439 Commitments and contingencies (Note 16) Stockholders' (deficit) equity Preferred stock, $ 0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 200,000 shares authorized as of June 30, 2025 and December 31, 2024; 6,620 and 3,102 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 60 49 Additional paid-in-capital 568,911 557,047 Accumulated deficit ( 676,638 ) ( 650,197 ) Total stockholders' (deficit) equity ( 107,667 ) ( 93,101 ) Total liabilities and stockholders' (deficit) equity $ 25,789 $ 38,338 The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents BIOXCEL THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousa

View Full Filing

View this 10-Q filing on SEC EDGAR